Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458437 | 0.91 | FAAH (0.46) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2455828 | 0.89 | FAAH (0.45) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2457526 | 0.88 | FAAH (0.44) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2457305 | 0.86 | FAAH (0.48) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2457062 | 0.85 | FAAH (0.46) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2461362 | 0.84 | FAAH (0.48) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2456933 | 0.84 | FAAH (0.62) | FAAHTNFGRM4 | |
| SCHEMBL2455528 | 0.83 | FAAH (0.46) | FAAHCCNE2CCNE1CDK2TNF | |
| SCHEMBL2458275 | 0.82 | FAAH (0.63) | FAAHSRCTNFGRM4 | |
| SCHEMBL2460744 | 0.82 | FAAH (0.46) | FAAHCDK2TNFTRPV1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | claimed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | FAAH, FAAH2, CNR2 | FAAH 1/4885SRC 4767/4885CCNE2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.